Although the oral application of mice with methyl indoxam, a pan-sPLA2 inhibitor, has been reported to suppress diet-induced obesity and glucose intolerance likely by inhibiting dietary phospholipid digestion with sPLA2-IB [89], the effect of this inhibitor on intestinal sPLA2-mediated regulation of the gut microflora [23,24] should also be considered. The gene discussed is PLA2G10; the disease is obesity disorder.